ArticleNature communications2017
A bioreducible N-oxide-based probe for photoacoustic imaging of hypoxia.
Article in Nature communications, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
74 citing papers in PubMed.
- Sequential HAngewandte Chemie (International ed. in English) · 2026Article
- One Stone Two Birds: Novel Fluorescent Probe Chemistry That Detects Redox Stress in Cell Culture.Analytical chemistry · 2026Article
- Hypoxia-Activated NIR-II Fluorescent Probes for Breast Tumor Imaging viaChemical & biomedical imaging · 2026Article
- Activatable smart contrast agents for photoacoustic imaging.Smart molecules : open access · 2026Review
- Fluorinated Hypoxia-Responsive Aza-BODIPY for NIR-II FL/Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Article
- Genetically Encoded Near-Infrared Fluorescent Proteins for Viral Imaging and Detection: A Mini-Review.Current microbiology · 2026Review
- Next-generation bacteriophage therapeutic systems: CRISPR-based engineering, near-infrared bioimaging, and precision strategies for treating multidrug-resistant and extensively drug-resistant bacterial infections.Frontiers in microbiology · 2026Review
- Clinical translation of photoacoustic imaging using exogenous molecular contrast agents [Invited].Biomedical optics express · 2025Review
- Acoustic loudness factor as an experimental parameter for benchmarking small molecule photoacoustic probes.Nature communications · 2025Article
- Logic-gated approach for targeted delivery and site-selective activation of photothermal agents in precision cancer treatment.Chemical science · 2025Article
- A hypoxia-activated and microenvironment-remodeling nanoplatform for multifunctional imaging and potentiated immunotherapy of cancer.Nature communications · 2024Article
- Modulating cancer mechanopathology to restore vascular function and enhance immunotherapy.Cell reports. Medicine · 2024Review
- Small-Molecule Fluorescent Probes for Binding- and Activity-Based Sensing of Redox-Active Biological Metals.Chemical reviews · 2024Review
- Recent advances in nanomaterial-driven strategies for diagnosis and therapy of vascular anomalies.Journal of nanobiotechnology · 2024Review
- Hypoxia-Directed and Self-Immolative Theranostic Agent: Imaging and Treatment of Cancer and Bacterial Infections.Journal of medicinal chemistry · 2023Article
- Cucurbit[8]uril-based water-dispersible assemblies with enhanced optoacoustic performance for multispectral optoacoustic imaging.Nature communications · 2023Article
- Activity-Based Photoacoustic Probes for Detection of Disease Biomarkers beyond Oncology.ACS bio & med chem Au · 2023Review
- Biomimetic Approach to Promote Cellular Uptake and Enhance Photoacoustic Properties of Tumor-Seeking Dyes.Journal of the American Chemical Society · 2023Article
- Review
14 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Hypoxia occurs when limited oxygen supply impairs physiological functions and is a pathological hallmark of many diseases including cancer and ischemia. Thus, detection of hypoxia can guide treatment planning and serve as a predictor of patient prognosis. Unfortunately, current methods suffer from invasiveness, poor resolution and low specificity. To address these limitations, we present Hypoxia Probe 1 (HyP-1), a hypoxia-responsive agent for photoacoustic imaging. This emerging modality converts safe, non-ionizing light to ultrasound waves, enabling acquisition of high-resolution 3D images in deep tissue. HyP-1 features an N-oxide trigger that is reduced in the absence of oxygen by heme proteins such as CYP450 enzymes. Reduction of HyP-1 produces a spectrally distinct product, facilitating identification via photoacoustic imaging. HyP-1 exhibits selectivity for hypoxic activation in vitro, in living cells, and in multiple disease models in vivo. HyP-1 is also compatible with NIR fluorescence imaging, establishing its versatility as a multimodal imaging agent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.